Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Updated from revision v3.4.2 to v3.4.3. This appears to be a minor internal version update with no visible changes to study details or user-facing features.
    Difference
    0.1%
    Check dated 2026-03-12T01:43:44.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and Revision: v3.4.1 was removed, both as site-wide versioning updates that do not affect the trial details or data on this page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T11:35:47.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a government funding–related notice about possible delays in updating information. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:18:10.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The page now includes a 'Show glossary' option, adds 'No FEAR Act Data' and 'Revision: v3.4.0' in the footer, and updates the label to 'Last Update Submitted that Met QC Criteria'.
    Difference
    0.2%
    Check dated 2026-01-28T04:59:04.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision v3.3.4 added and revision v3.3.3 removed; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:22:59.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A new study location in Illinois was added and the footer revision updated to v3.3.3; the HHS Vulnerability Disclosure entry was removed.
    Difference
    0.2%
    Check dated 2025-12-23T17:21:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.